•
OR
ORIC
Oric Pharmaceuticals, Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
1.19B
Volume
1.34M
52W High
$14.93
52W Low
$3.90
Open
$0.00
Prev Close
$11.62
Day Range
0.00 - 0.00
About Oric Pharmaceuticals, Inc. Common Stock
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Latest News
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
Benzinga•Jan 14
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
GlobeNewswire Inc.•Dec 6
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
GlobeNewswire Inc.•Dec 5
ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor
GlobeNewswire Inc.•Nov 6
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Jun 6
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Feb 7
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
Benzinga•Jan 15
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Jan 3